GE release decision-making software
A product released this week by GE Healthcare is designed to give physicians information about clinical data and best treatment practices, where and when they need it.
GE release decision-making software
A product released this week by GE Healthcare is designed to give physicians information about clinical data and best treatment practices, where and when they need it. The computerized decision support solution, developed with Intermountain Healthcare and drawing on its three decades of clinical informatics experience, is intended for use at the point of care. It promises to help improve patient outcomes and efficiency, ultimately helping to reduce costs, according to GE. Intermountain will begin using the software next month in its clinical practices. GE will unveil the full product at the March 2010 meeting of the Healthcare Information Management and Systems Society. The new technology enables real-time clinical review, capturing vital data from electronic medical records and signaling the physician if the proposed actions vary from accepted practice standards.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
